High-density lipoprotein-targeted therapy and apolipoprotein A-I mimetic peptides

Circulation Journal

Volumn 79, Issue 12, 2015, Pages 2523-2528

  Uehara, Yoshinari ^a,b   Chiesa, Giulia ^c   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Apolipoprotein; Atherosclerosis; Cardiovascular disease; Dyslipidemia; Reverse cholesterol transport

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; ETC 216; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN; PRAVASTATIN; ROSUVASTATIN; TORCETRAPIB; APOA1 PROTEIN, HUMAN; BIOMIMETIC MATERIAL; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEPTIDE;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; ELECTROPHORETIC MOBILITY; GENETIC DISORDER; HUMAN; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; POINT MUTATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG DELIVERY SYSTEM; PROCEDURES;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BIOMIMETIC MATERIALS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG DELIVERY SYSTEMS; HUMANS; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84978955143     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0960     Document Type: Review

References (67)

1. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis: Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21: 13 - 27.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: The Framingham study. Am J Med 1977; 62: 707 - 714.
3. Assmann G. Genes and dyslipoproteinaemias. Eur Heart J 1990; 11(Suppl H): 4 - 8.
4. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis. BMJ 2009; 338: b92.
5. Saku K, Zhang B, Noda K, Investigators PT. Randomized head-tohead comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): The PATROL trial. Circ J 2011; 75: 1493 - 1505.
6. Soeda T, Uemura S, Okayama S, Kawakami R, Sugawara Y, Nakagawa H, et al. Intensive lipid-lowering therapy with rosuvastatin stabilizes lipid-rich coronary plaques: Evaluation using dualsource computed tomography. Circ J 2011; 75: 2621 - 2627.
7. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345 - 1353.
8. Kunitake ST, La Sala KJ, Kane JP. Apolipoprotein A-I-containing lipoproteins with pre-beta electrophoretic mobility. J Lipid Res 1985; 26: 549 - 555.
9. Ishida BY, Frolich J, Fielding CJ. Prebeta-migrating high density lipoprotein: Quantitation in normal and hyperlipidemic plasma by solid phase radioimmunoassay following electrophoretic transfer. J Lipid Res 1987; 28: 778 - 786.
10. Miller M, Rhyne J, Hamlette S, Birnbaum J, Rodriguez A. Genetics of HDL regulation in humans. Curr Opin Lipidol 2003; 14: 273 - 279.
11. Oram JF, Lawn RM. ABCA1: The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 2001; 42: 1173 - 1179.
12. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 160 - 167.
13. Yamashita S, Sprecher DL, Sakai N, Matsuzawa Y, Tarui S, Hui DY. Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J Clin Invest 1990; 86: 688 - 695.
14. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004; 24: 490 - 497.
15. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350: 1505 - 1515.
16. Ikewaki K, Rader DJ, Sakamoto T, Nishiwaki M, Wakimoto N, Schaefer JR, et al. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 1993; 92: 1650 - 1658.
17. Tall AR. Plasma high density lipoproteins: Metabolism and relationship to atherogenesis. J Clin Invest 1990; 86: 379 - 384.
18. Cuchel M, Rader DJ. Genetics of increased HDL cholesterol levels: Insights into the relationship between HDL metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 1710 - 1712.
19. Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: Insights from ILLUSTRATE (investigation of lipid level management using coronary ultrasound to assess reduction of atherosclerosis by CETP inhibition and HDL elevation). Circulation 2008; 118: 2506 - 2514.
20. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (Radiance 2 study): A randomised, double-blind trial. Lancet 2007; 370: 153 - 160.
21. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 1620 - 1630.
22. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304 - 1316.
23. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): A randomised clinical trial. Lancet 2011; 378: 1547 - 1559.
24. Luscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Munzel T, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: The dal-VESSEL randomized clinical trial. Eur Heart J 2012; 33: 857 - 865.
25. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089 - 2099.
26. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495 - 1504.
27. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW 3rd, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009; 157: 352 - 360.e2, doi:10.1016/j.ahj.2008.09.022.
28. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: Arandomized controlled trial. JAMA 2011; 306: 2099 - 2109.
29. Cao G, Beyer TP, Zhang Y, Schmidt RJ, Chen YQ, Cockerham SL, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res 2011; 52: 2169 - 2176.
30. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, et al. Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009; 158: 896 - 901.e3, doi:10.1016/j. ahj.2009.09.017.
31. Moore RE, Kawashiri MA, Kitajima K, Secreto A, Millar JS, Pratico D, et al. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. Arterioscler Thromb Vasc Biol 2003; 23: 1914 - 1920.
32. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94: 899 - 903.
33. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994; 91: 9607 - 9611.
34. Annema W, von Eckardstein A. High-density lipoproteins: Multifunctional but vulnerable protections from atherosclerosis. Circ J 2013; 77: 2432 - 2448.
35. Zhang B, Kawachi E, Miura S, Uehara Y, Matsunaga A, Kuroki M, et al. Therapeutic approaches to the regulation of metabolism of high-density lipoprotein: Novel HDL-directed pharmacological intervention and exercise. Circ J 2013; 77: 2651 - 2663.
36. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004; 101: 9774 - 9779.
37. Rye KA, Hime NJ, Barter PJ. Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion. J Biol Chem 1997; 272: 3953 - 3960.
38. Uehara Y, Tsuboi Y, Zhang B, Miura S, Baba Y, Higuchi MA, et al. POPC/ApoA-I discs as a potent lipoprotein modulator in Tangier disease. Atherosclerosis 2008; 197: 283 - 289.
39. Iwata A, Miura S, Zhang B, Imaizumi S, Uehara Y, Shiomi M, et al. Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits. Atherosclerosis 2011; 218: 300 - 307.
40. Weisgraber KH, Bersot TP, Mahley RW, Franceschini G, Sirtori CR. A-IMilano apoprotein: Isolation and characterization of a cysteinecontaining variant of the A-I apoprotein from human high density lipoproteins. J Clin Invest 1980; 66: 901 - 907.
41. Gualandri V, Franceschini G, Sirtori CR, Gianfranceschi G, Orsini GB, Cerrone A, et al. AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 1985; 37: 1083 - 1097.
42. Favari E, Gomaraschi M, Zanotti I, Bernini F, Lee-Rueckert M, Kovanen PT, et al. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding cassette A1-mediated cell cholesterol efflux. J Biol Chem 2007; 282: 5125 - 5132.
43. Franceschini G, Calabresi L, Chiesa G, Parolini C, Sirtori CR, Canavesi M, et al. Increased cholesterol efflux potential of sera from apoA-IMilano carriers and transgenic mice. Arterioscler Thromb Vasc Biol 1999; 19: 1257 - 1262.
44. Parolini C, Marchesi M, Lorenzon P, Castano M, Balconi E, Miragoli L, et al. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: In vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol 2008; 51: 1098 - 1103.
45. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003; 290: 2292 - 2300.
46. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Crowe T, Kapadia S, et al. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 2006; 47: 992 - 997.
47. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004; 291: 1071 - 1080.
48. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006; 295: 1556 - 1565.
49. Fredrickson DS, Altrocchi PH, Avioli LV, Goodman DS, Goodman HC. Tangier disease: Combined clinical staff conference at the National Institutes of Health. Ann Intern Med 1961; 55: 1016 - 1031.
50. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999; 22: 336 - 345.
51. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22: 347 - 351.
52. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, et al. Tangier disease is caused by mutations in the gene encoding ATPbinding cassette transporter 1. Nat Genet 1999; 22: 352 - 355.
53. Orso E, Broccardo C, Kaminski WE, Bottcher A, Liebisch G, Drobnik W, et al. Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and ABC1-deficient mice. Nat Genet 2000; 24: 192 - 196.
54. McNeish J, Aiello RJ, Guyot D, Turi T, Gabel C, Aldinger C, et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci USA 2000; 97: 4245 - 4250.
55. Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD, et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest 2001; 108: 303 - 309.
56. Singaraja RR, Bocher V, James ER, Clee SM, Zhang LH, Leavitt BR, et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and apoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J Biol Chem 2001; 276: 33969 - 33979.
57. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, et al. Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105: 290 - 292.
58. Li X, Chyu KY, Faria Neto JR, Yano J, Nathwani N, Ferreira C, et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004; 110: 1701 - 1705.
59. Remaley AT, Thomas F, Stonik JA, Demosky SJ, Bark SE, Neufeld EB, et al. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res 2003; 44: 828 - 836.
60. Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, Lehrer RI, et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 2008; 49: 2302 - 2311.
61. Uehara Y, Ando S, Oniki K, Abe S, Yahiro E, Tanigawa H, et al. FAMP, a novel apoA-I mimetic peptide promotes HDL via ABCA1- dependent cholesterol efflux. Atherosclerosis Suppl 2010; 11: 3.
62. Uehara Y, Ando S, Yahiro E, Oniki K, Ayaori M, Abe S, et al. FAMP, a novel apoA-I mimetic peptide, suppresses aortic plaque formation through promotion of biological HDL function in apoEdeficient mice. J Am Heart Assoc 2013; 2: e000048, doi:10.1161/ JAHA.113.000048.
63. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127 - 135.
64. Shimizu T, Tanigawa H, Miura S, Kuwano T, Takata K, Suematsu Y, et al. Newly developed apolipoprotein A-I mimetic peptide promotes macrophage reverse cholesterol transport in vivo. Int J Cardiol 2015; 192: 82 - 88.
65. Arnaboldi F, Busnelli M, Cornaghi L, Manzini S, Parolini C, Dellera F, et al. High-density lipoprotein deficiency in genetically modified mice deeply affects skin morphology: A structural and ultrastructural study. Exp Cell Res 2015; 338: 105 - 112.
66. Kawachi E, Uehara Y, Hasegawa K, Yahiro E, Ando S, Wada Y, et al. Novel molecular imaging of atherosclerosis with gallium-68-labeled apolipoprotein A-I mimetic peptide and positron emission tomography. Circ J 2013; 77: 1482 - 1489.
67. Uchida Y, Hiruta N, Yamanoi D, Shimoyama E, Maezawa Y, Uchida Y. Imaging of native high-density lipoprotein in human coronary plaques by color fluorescent angioscopy. Circ J 2014; 78: 1667 - 1675.